vs
Grove Collaborative Holdings, Inc.（GROV）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Grove Collaborative Holdings, Inc.的季度营收约是REGENXBIO Inc.的1.4倍（$42.4M vs $30.3M），Grove Collaborative Holdings, Inc.净利率更高（-3.7% vs -221.3%，领先217.6%），REGENXBIO Inc.同比增速更快（43.0% vs -14.3%），Grove Collaborative Holdings, Inc.自由现金流更多（$-62.0K vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -11.0%）
Grove Collaborative控股公司是一家公益企业，总部位于美国旧金山，在缅因州波特兰设有额外办事处。该企业以自有品牌Grove Co.推出并销售自有环保家居及个人护理产品，同时也代理销售其他品牌的相关产品，主打绿色可持续的日用消费品类目。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
GROV vs RGNX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $42.4M | $30.3M |
| 净利润 | $-1.6M | $-67.1M |
| 毛利率 | 53.0% | — |
| 营业利润率 | -3.7% | -190.0% |
| 净利率 | -3.7% | -221.3% |
| 营收同比 | -14.3% | 43.0% |
| 净利润同比 | 87.5% | -31.2% |
| 每股收益（稀释后） | $-0.06 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $42.4M | $30.3M | ||
| Q3 25 | $43.7M | $29.7M | ||
| Q2 25 | $44.0M | $21.4M | ||
| Q1 25 | $43.5M | $89.0M | ||
| Q4 24 | $49.5M | $21.2M | ||
| Q3 24 | $48.3M | $24.2M | ||
| Q2 24 | $52.1M | $22.3M | ||
| Q1 24 | $53.5M | $15.6M |
| Q4 25 | $-1.6M | $-67.1M | ||
| Q3 25 | $-3.0M | $-61.9M | ||
| Q2 25 | $-3.6M | $-70.9M | ||
| Q1 25 | $-3.5M | $6.1M | ||
| Q4 24 | $-12.6M | $-51.2M | ||
| Q3 24 | $-1.3M | $-59.6M | ||
| Q2 24 | $-10.1M | $-53.0M | ||
| Q1 24 | $-3.4M | $-63.3M |
| Q4 25 | 53.0% | — | ||
| Q3 25 | 53.3% | — | ||
| Q2 25 | 55.4% | — | ||
| Q1 25 | 53.0% | — | ||
| Q4 24 | 52.4% | 70.2% | ||
| Q3 24 | 53.0% | 48.8% | ||
| Q2 24 | 53.9% | 52.5% | ||
| Q1 24 | 55.5% | 72.6% |
| Q4 25 | -3.7% | -190.0% | ||
| Q3 25 | -6.2% | -176.3% | ||
| Q2 25 | -7.9% | -296.3% | ||
| Q1 25 | -8.1% | 13.6% | ||
| Q4 24 | -16.8% | -242.1% | ||
| Q3 24 | -14.0% | -256.6% | ||
| Q2 24 | -13.3% | -251.3% | ||
| Q1 24 | -1.0% | -408.8% |
| Q4 25 | -3.7% | -221.3% | ||
| Q3 25 | -6.8% | -208.3% | ||
| Q2 25 | -8.2% | -331.8% | ||
| Q1 25 | -8.1% | 6.8% | ||
| Q4 24 | -25.5% | -241.3% | ||
| Q3 24 | -2.8% | -246.3% | ||
| Q2 24 | -19.3% | -237.7% | ||
| Q1 24 | -6.3% | -405.4% |
| Q4 25 | $-0.06 | $-1.30 | ||
| Q3 25 | $-0.08 | $-1.20 | ||
| Q2 25 | $-0.10 | $-1.38 | ||
| Q1 25 | $-0.10 | $0.12 | ||
| Q4 24 | $-0.34 | $-0.99 | ||
| Q3 24 | $-0.04 | $-1.17 | ||
| Q2 24 | $-0.28 | $-1.05 | ||
| Q1 24 | $-0.10 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.5M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-17.0M | $102.7M |
| 总资产 | $53.1M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $8.5M | $230.1M | ||
| Q3 25 | $8.9M | $274.2M | ||
| Q2 25 | $10.0M | $323.3M | ||
| Q1 25 | $9.6M | $267.9M | ||
| Q4 24 | $19.6M | $234.7M | ||
| Q3 24 | $50.8M | $255.5M | ||
| Q2 24 | $78.8M | $290.4M | ||
| Q1 24 | $77.8M | $338.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $32.2M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-17.0M | $102.7M | ||
| Q3 25 | $-16.1M | $161.5M | ||
| Q2 25 | $-14.0M | $213.7M | ||
| Q1 25 | $-11.6M | $274.2M | ||
| Q4 24 | $-8.5M | $259.7M | ||
| Q3 24 | $1.5M | $301.4M | ||
| Q2 24 | $686.0K | $348.3M | ||
| Q1 24 | $7.5M | $390.7M |
| Q4 25 | $53.1M | $453.0M | ||
| Q3 25 | $54.6M | $525.2M | ||
| Q2 25 | $57.8M | $581.0M | ||
| Q1 25 | $59.8M | $490.9M | ||
| Q4 24 | $65.0M | $466.0M | ||
| Q3 24 | $105.2M | $519.1M | ||
| Q2 24 | $131.8M | $569.4M | ||
| Q1 24 | $137.9M | $629.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 21.16× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-29.0K | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-62.0K | $-52.8M |
| 自由现金流率自由现金流/营收 | -0.1% | -174.0% |
| 资本支出强度资本支出/营收 | 0.1% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-8.1M | $-126.4M |
8季度趋势，按日历期对齐
| Q4 25 | $-29.0K | $-52.3M | ||
| Q3 25 | $-1.0M | $-56.0M | ||
| Q2 25 | $987.0K | $-49.3M | ||
| Q1 25 | $-6.9M | $33.6M | ||
| Q4 24 | $270.0K | $-31.6M | ||
| Q3 24 | $750.0K | $-40.5M | ||
| Q2 24 | $1.6M | $-45.5M | ||
| Q1 24 | $-12.4M | $-55.5M |
| Q4 25 | $-62.0K | $-52.8M | ||
| Q3 25 | $-1.2M | $-56.5M | ||
| Q2 25 | $556.0K | $-49.7M | ||
| Q1 25 | $-7.4M | $32.6M | ||
| Q4 24 | $-95.0K | $-32.7M | ||
| Q3 24 | $264.0K | $-40.9M | ||
| Q2 24 | $1.2M | $-46.0M | ||
| Q1 24 | $-12.9M | $-56.0M |
| Q4 25 | -0.1% | -174.0% | ||
| Q3 25 | -2.7% | -189.9% | ||
| Q2 25 | 1.3% | -232.8% | ||
| Q1 25 | -17.0% | 36.6% | ||
| Q4 24 | -0.2% | -154.2% | ||
| Q3 24 | 0.5% | -168.9% | ||
| Q2 24 | 2.3% | -206.2% | ||
| Q1 24 | -24.1% | -358.5% |
| Q4 25 | 0.1% | 1.7% | ||
| Q3 25 | 0.4% | 1.7% | ||
| Q2 25 | 1.0% | 1.8% | ||
| Q1 25 | 1.2% | 1.2% | ||
| Q4 24 | 0.7% | 5.1% | ||
| Q3 24 | 1.0% | 1.3% | ||
| Q2 24 | 0.7% | 2.1% | ||
| Q1 24 | 1.0% | 3.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GROV
| Third Party Products | $23.4M | 55% |
| Grove Brands | $19.0M | 45% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
